Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania

This study aimed to identify and describe anatomical and functional changes on short (1–3 months) and medium (6–12 months) term after intravitreal injections of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) in the context of exudative form of age-related macula...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanca, Horia T., Stanca, Simona, Tabacaru, Bogdana, Boruga, Madalina, Balta, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880423/
https://www.ncbi.nlm.nih.gov/pubmed/31798721
http://dx.doi.org/10.3892/etm.2019.7858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880423/
https://www.ncbi.nlm.nih.gov/pubmed/31798721
http://dx.doi.org/10.3892/etm.2019.7858

Ejemplares similares